assessment naturally became a valued-and, indeed, expectedcomponent of the care that I delivered. In light of this experience, I believe we should consider other professionals' expectations and opinions about our role, but we should never let them dissuade us from practising to our full scope. After all, before the 1960s, no one expected to see pharmacists working on the wards. 
I read with interest the study by Chevalier and colleagues in the November-December 2016 issue of the Canadian Journal of Hospital Pharmacy.
1 Briefly, the authors administered a survey on expectations for various domains of pharmaceutical care to the nurses and physicians of a surgical ward before and 8 months after implementation of clinical pharmacy services. I was intrigued by the low proportion of respondents from each profession who felt that "conducting basic physical assessments" was an expected role for a clinical pharmacist on the surgical ward. Here, I elaborate on possible explanations for these results, and share some of my own experiences as a clinical pharmacist incorporating physical assessment on a surgical ward.
Before implementation of clinical pharmacy services in the study reported by Chevalier and colleagues, 1 12% and 0% of nurse and physician respondents, respectively, agreed that conducting basic physical assessment was an expected role of clinical pharmacists on surgical wards; these proportions remained virtually unchanged, at 11% and 0%, respectively, in the followup survey. Given the many physical manifestations of adverse drug events, these results contradict the high proportions of respondents who expected pharmacists to identify adverse drug reactions. 1 Indeed, based on countless discussions with nurses and physicians about pharmacist-performed physical assessment, I would suggest that the vague description of "basic" physical assessment in this survey likely resulted in a substantial proportion of respondents unfamiliar with the concept interpreting it as "pharmacists making medical diagnoses". However, the purpose of pharmacistperformed physical assessment is to complement the rest of the clinical assessment in identifying and monitoring for the resolution of drug-related problems. There is variation among pharmacists in the complexity of physical assessment performed in their practice, but every clinical pharmacist performs an inspection, the most "basic" form of physical assessment, every time they meet and engage in discussion with a patient, identifying findings relevant to drug therapy, such as discomfort, altered mental status, and conspicuous rashes. With various techniques becoming standard in entry-to-practice pharmacy education, we must be diligent in clearly defining the role and scope of pharmacist-performed physical assessment.
I offer details about my use of physical assessment in a neurosurgical ward to illustrate that pharmacist-performed physical assessment can improve patient care in a surgical ward, and can come to be highly valued by nurses and physicians. I took on the role of clinical pharmacist for the neurosurgical service of a quaternary care hospital in 2015 after completing my residency and PharmD training, which incorporated didactic and hands-on education related to physical assessment. I immediately began looking for ways to incorporate physical assessment into my practice. At first, nurses and (particularly) physicians were skeptical, but they soon accepted the role of physical assessment in my overall assessments, especially after hearing my brief explanation as to how I was incorporating it into my pharmaceutical care plans, and seeing it in action.
Over the course of about 3 months, I observed the processes of care on the neurosurgical ward and identified key disease states and drugs that would benefit from pharmacist-performed physical assessment. For example, in settings where I had previously practised, such as an internal medicine clinical teaching unit, medical staff routinely performed comprehensive volume assessments in inpatients with heart failure or cirrhosis with ascites, such that I could easily interpret these data and integrate them into my recommendations. However, I noticed that for the many patients admitted to neurosurgery for intracranial hemorrhage who had concomitant heart failure, this information was not readily available. Because I had the training to do so, I began performing comprehensive volume assessments, including examination of the jugular venous pulsation, heart, and lungs, in these patients to collect and document these data. Other notable examples included monitoring for resolution of postoperative complications, such as pneumonia and wound infections, and identifying the physical manifestations of antipsychotic-induced oculogyric crisis in a patient previously presumed to have focal seizures.
In all cases, I collaborated with my nurse and physician colleagues in enacting a pharmaceutical care plan to resolve these significant drug-related problems. As I fostered interprofessional relationships with the rest of the neurosurgical team, physical
The 2016 Clinical Practice Guidelines for Management of Hospital-Acquired and Ventilator-Associated Pneumonia
Hospital-acquired pneumonia and ventilator-associated pneumonia are defined as occurring at least 48 h after admission or endotracheal intubation, respectively.
1 Until recently, evidence-based guidelines for treating these illnesses were quite dated. The last edition of the guideline prepared by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) was published in 2005, 2 and the latest Canadian national guidelines, prepared by the Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada), were published in 2008. 3 The 2016 IDSA/ATS update 1 was therefore much-awaited, and it includes several significant changes to recommendations from the previous edition.
For pharmacists, perhaps the most relevant changes are those concerning recommended empiric antimicrobial regimens. Determination of risk factors for multidrug-resistant (MDR) pathogens continues to be promoted for therapeutic decisionmaking.
1 However, the factors to consider have been modified for greater precision. For example, because of inconsistent data linking the timing of pneumonia onset with MDR pathogens, the distinction between early-and late-onset hospital-acquired pneumonia has been removed.
1 Although the 2016 update continues to list "5 or more days of hospitalization preceding pneumonia occurrence" as a risk factor for MDR pathogens, this now applies to ventilator-associated pneumonia only and is superseded by the presence of other risk factors.
1 On a related note, the concept of health care-associated pneumonia has been removed entirely, with an expectation that the risk factors for MDR pathogens associated with this previously recognized entity will be refined and included in forthcoming guidelines for community-acquired pneumonia. 1 Importantly, despite greater nuance in identifying the risk of MDR pathogens, recommended empiric antimicrobial regimens are now more uniformly broad-spectrum. For example, at least one antipseudomonal agent is now recommended for both hospital-acquired and ventilator-associated pneumonia, regardless of patient-specific risk factors.
1 This new recommendation contrasts with the 2005 edition, 2 which listed regimens with no pseudomonal coverage (e.g., ceftriaxone or moxifloxacin monotherapy) as alternatives for early-onset hospital-acquired or ventilator-associated pneumonia in patients without risk factors for MDR pneumonia. The rationale for recommending broader empiric coverage for patients without increased risk for MDR infection is not provided. 1 In fact, even in patients with hospital-acquired pneumonia who are regarded to be at increased risk of infection with an MDR pathogen but who have mild or moderate illness, the AMMI Canada guidelines list ceftriaxone and moxifloxacin monotherapy as suitable options.
3 Empiric antipseudomonal coverage is required only for patients with severe illness (e.g., hypotension, organ dysfunction, hypoxia associated with need for mechanical ventilation) and in those with suspected Pseudomonas aeruginosa infection.
3 Therefore, strict adherence to the 2016 IDSA/ATS recommendations could lead to more widespread use of broadspectrum antipseudomonal antibiotics in the Canadian population of patients with hospital-acquired or ventilator-associated pneumonia.
A shift in practice of this nature should compel us to ask whether following the IDSA/ATS recommendations will improve patient outcomes. Although there are no data specifically related to the 2016 IDSA/ATS guidelines, a 2011 study called into question the benefits of adhering to the previous edition of these guidelines. 4 This prospective, observational study of intensive care patients at risk for MDR pneumonia examined whether outcomes were better among patients who received empiric therapy compliant with the 2005 IDSA/ATS guidelines than among those who received noncompliant therapy. 4 The authors found that 89% of noncompliance was due to non-use of dual treatment for gram-negative pathogens. 4 Guideline adherence was associated with higher 28-day mortality, regardless of the identified pathogen (adjusted hazard ratio 1.56, 95% confidence interval 1.00-2.44). 4 The authors proposed that this finding could reflect the excess harm versus benefit associated with combination gram-negative treatment.
